Precision Vascular has developed a proprietary line of guidewires and microcatheters for accessing brain aneurysms, tumors and other blood vessel lesions of the brain. Boston Scientific's Target division expects to begin distribution of Precision Vascular's guidewires early in the fourth quarter of this year. Target is a leading developer of medical technologies used by endovascular neurosurgeons and interventional neuroradiologists. The Precision Vascular distribution agreement will expand Target's interventional neuroradiology product portfolio, which also includes GDC® and Matrix™ coils for the treatment of brain aneurysms.

Precision Vascular's technology platform is based on microfabrication techniques that enable development of high performance access devices. In addition to its current portfolio of approved devices for use in the brain, Precision Vascular plans to apply its technology to develop interventional products for vascular disorders in cardiology, radiology and oncology.

"We are extremely impressed with the Precision Vascular team, particularly their ability to develop guidewires which can navigate difficult anatomies," said Jim Feenstra, President of Boston Scientific's Target division. "Many physicians have already evaluated their products and have clinically demonstrated their improvement over conventional devices."

"We are pleased that Boston Scientific has made this commitment to Precision Vascular's technology," said Ken Osborn, President of Precision Vascular. "The investment, along with Boston Scientific's worldwide distribution power, will allow interventional physicians to access our unique products for the treatment of many vascular disorders."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices. The company's products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, regulatory approvals, competitive offerings, intellectual property rights, including those of third parties, consummating acquisition transactions and subsequent integration efforts, the company's overall business strategy, and other factors described in the company's filings with the Securities and Exchange Commission.